Abpro Holdings Takes a Leap Forward in Cancer Treatment
In a promising advancement for cancer therapeutics, Abpro Holdings, Inc. has officially submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for its innovative T cell engager, ABP-102/CT-P72. Developed in collaboration with Celltrion, Inc., this groundbreaking therapy is designed to specifically target HER2-positive cancers, which can include challenging conditions such as breast and gastric cancers.
Significant Milestone for Abpro
This IND submission signifies Abpro’s first-ever for a phase 1 clinical trial targeting a solid tumor indication. The submission is based on preclinical studies demonstrating that ABP-102/CT-P72 has enhanced selectivity towards HER2-high tumors while maintaining a positive safety profile. The study is set to commence in the first half of 2026, pending FDA approval, marking a crucial step in the ongoing development of innovative cancer therapies.
Promising Preclinical Results
Recent presentations at esteemed cancer research conferences, such as the American Association for Cancer Research (AACR) and the Society for Immunotherapy of Cancer (SITC), highlighted the compelling preclinical efficacy of ABP-102/CT-P72. The outcomes showed the therapy's robust activity against HER2-high tumor models, while exhibiting reduced effects on normal tissues, indicating the potential for a favorable therapeutic index.
CEO Miles Suk on the Progress
Commenting on this important achievement, Miles Suk, CEO of Abpro, expressed enthusiasm about advancing to the IND review stage. He stated that this milestone underscores the strength of their T cell engager platform and the fruitful collaboration between Abpro and Celltrion. The goal remains to deliver a selective therapeutic option for patients facing HER2-positive solid tumors, especially those who have limited alternatives available.
The Path Ahead: Phase 1 Study
Once approved, the phase 1 study will primarily assess the safety, pharmacokinetics, and initial efficacy of ABP-102/CT-P72 through a structured dose-escalation and dose-expansion format. Insights gathered from the clinical trial will significantly inform dose determination and subsequent research pathways.
About Abpro Holdings
Abpro Holdings is dedicated to enhancing the lives of individuals battling severe and life-threatening diseases through next-generation antibody therapies. The company is actively developing a diverse pipeline targeting a range of conditions, including HER2-positive cancers, non-HER2+ gastric and liver cancer, as well as eye diseases like wet age-related macular degeneration and diabetic macular edema. Leveraging its proprietary DiversImmune platform, Abpro is at the forefront of innovating therapies that promise to make a difference.
About Celltrion
Celltrion, renowned for its significant contributions in the biopharmaceutical landscape, is grounded in South Korea. The company is dedicated to researching, developing, and manufacturing innovative therapeutic solutions that aim to improve global health. With a focus on sustainable growth and ethical practices, Celltrion is committed to bringing advanced healthcare technology to various patients worldwide.
Frequently Asked Questions
What is ABP-102/CT-P72?
ABP-102/CT-P72 is a T cell engager developed by Abpro Holdings that targets HER2-positive cancers, designed to enhance tumor selectivity while minimizing effects on normal tissues.
What is the significance of the IND submission?
The IND submission represents a pivotal milestone for Abpro as it seeks regulatory approval to initiate a phase 1 clinical trial for a new cancer therapy.
When is the phase 1 trial expected to start?
The phase 1 trial for ABP-102/CT-P72 is anticipated to begin in the first half of 2026, pending regulatory clearance.
Who is collaborating with Abpro on this project?
Abpro is co-developing ABP-102/CT-P72 in partnership with Celltrion, Inc., enhancing their collective research and development capabilities.
What types of cancers will the trial target?
The trial will focus on patients with HER2-positive cancers, including those suffering from breast and gastric types, which are often aggressive and challenging to treat.
